Can morbidity and mortality of SLE be improved?

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 2, 2002, Pages 313-332

  Bongu, Anurekha ^a   Chang, Elizabeth ^a   Ramsey Goldman, Rosalind ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epidemiology; Morbidity; Mortality; Systemic lupus erythematosus

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTROGEN; IMMUNOSUPPRESSIVE AGENT; ORAL CONTRACEPTIVE AGENT; VITAMIN D; ANABOLIC AGENT; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CYTOTOXIC AGENT; GLUCOCORTICOID; HORMONE; HYDROXYCHLOROQUINE; MESNA; METHOTREXATE; NIFEDIPINE; PARATHYROID HORMONE; PREDNISOLONE; PREDNISONE; VACCINE;

AUTOIMMUNE DISEASE; BONE NECROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL TRIAL; DATA BASE; DISEASE ACTIVITY; ETHNIC GROUP; EUROPE; GENDER; HEALTH SERVICE; HUMAN; KIDNEY INJURY; MENTAL DISEASE; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RACE; REVIEW; RISK FACTOR; SOCIAL STATUS; SUBLUXATION; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TENOSYNOVITIS; UNITED STATES; UTERINE CERVIX CANCER; VASCULITIS; AGE; AVASCULAR NECROSIS; BLADDER IRRIGATION; BLADDER IRRITATION; CANCER; DEATH; DECOMPRESSION SURGERY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROSTIMULATION; ETHNIC DIFFERENCE; ETHNOLOGY; EYE DISEASE; HEART INFARCTION; HORMONE SUBSTITUTION; INCIDENCE; INFECTION; JOINT PROSTHESIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LONG TERM CARE; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MUSCULOSKELETAL DISEASE; OSTEOTOMY; PHYSIOTHERAPY; POPULATION RISK; PREVALENCE; PROPHYLAXIS; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL; TENDON DISEASE; ULTRASOUND THERAPY; VACCINATION; FEMALE;

AGE FACTORS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MORBIDITY; MORTALITY; SEX FACTORS;

EID: 0036527773     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0228     Document Type: Article

References (151)

1. Lin SS & Kelsey J. Use of race and ethnicity in epidemiologic research: Concepts, methodologic issues, and suggestions for research. Epidemiology Reviews 2000; 22: 187-202.
2. Brooks K, Fessler B, Bastian H & Alarcon G. Sociocultural issues in clinical research. Arthritis Care Research 2001; 45: 203-207.
3. Siegal M & Lee S. The epidemiology of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 1973; 3: 1-54.
4. Michet J Jr, McKenna C, Elveback L et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950-1979. Mayo Clinic Proceedings 1985; 60: 105-113.
5. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis & Rheumatism 1985; 28: 80-86.
6. Fessel W. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms: The high prevalence in black women. Archives of Internal Medicine 1974; 134: 1027-1035.
7. Johnson A, Gordon C, Palmer R & Bacon P. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis & Rheumatism 1995; 53: 551-558.
8. Samanta A, Feehally J, Roy S et al. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1991; 50: 490-492.
9. Feehally J, Burden AC, Mayberry JF et al. Disease variations in Asians in Leicester. Quarterly Journal of Medicine 1993; 86: 263-269.
10. Gudmundsson S & Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. Journal of Rheumatology 1990; 17: 1162-1167.
11. Stahl-Hallengren C, Jonsen A, Nived O & Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis. Journal of Rheumatology 2000; 27: 685-691.
12. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of SLE. Arthritis & Rheumatism 1982; 25: 1271-1277.
13. McCarty DJ, Manzi S, Medsger TA Jr et al. Incidence of SLE: Race and gender differences. Arthritis & Rheumatism 1995; 38: 1260-1270.
14. Hopkinson N, Doherty M & Powell R. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Annals of the Rheumatic Diseases 1994; 53: 675-680.
15. Symmons D. Occasional series-lupus around the world. Frequency of lupus in people of African origin. Lupus 1995; 4: 176-178.
16. Bae S-C, Fraser P & Liang M. The prevalence and incidence of systemic lupus erythematosus in populations in African ancestry: A critical review of the "prevalence gradient hypothesis". Arthritis & Rheumatism 1998; 41: 2091-2099.
17. Acers T, Acers-Wam A et al. Incidence patterns of immunogenetic diseases in the North American Indians. Journal of the Oklahoma State Medical Association 1994; 87: 309-314.
18. Boyer G, Templin D & Lanier A. Rheumatic diseases in Alaskan Indians of the southeast coast: High prevalence of rheumatoid arthritis and systemic lupus erythematosus. Journal of Rheumatology 1991; 18: 1477-1484.
19. Atkins C, Rueffel L & Roddy J et al. Rheumatic disease in the Nuu-chah-Nulth Native Indians of the pacific northwest. Journal of Rheumatology 1988; 15: 684-690.
20. Morton R, Gershwin ME, Brady C & Steinberg A. The incidence of systemic lupus erythematosus in North American Indians. Journal of Rheumatology 1976; 3: 186-190.
21. Maskarince G & Katz A. Prevalence of systemic lupus erythematosus in Hawaii: Is there a difference between ethnic groups? Hawaii Medical Journal 1995; 54: 406-409.
22. Serdula M & Rhoads G. Frequency of SLE in different ethnic groups in Hawaii. Arthritis & Rheumatism 1979; 22: 328-333.
23. Nai-Cheng C. Rheumatic diseases in China. Journal of Rheumatology 1976; 3: 186-190.
24. Chou C-T, Lee F-T & Schumacher H. Modification of a screening technique to evaluate SLE in a chinese population in Taiwan. Journal of Rheumatology 1986; 13: 806-809.
25. Alarcon G, McGwin GJ, Bastian H et al. Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Care Research 2001; 45: 191-202.
26. US Bureau of the Census: Current Population Reports Series. Population Profile of the United States, 1997. Washington, DC: US Government Printing Office, 1998.
27. Escalante A & Del Rincon I. Epidemiology and impact of rheumatic disorders in the United States Hispanic population. Current Opinion in Rheumatology 2001; 13: 104-110.
28. Merrell M & Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. Journal of Chronic Diseases 1955; 1: 12-32.
29. Abu-Shakra M, Urowitz MB, Gladman DD & Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II Predictor variables for mortality. Journal of Rheumatology 1995; 22: 1265-1270.
30. Cervera R, Khamastha M, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. Medicine 1999; 78: 167-175.
31. Massardo L, Martinez M, Jacobelli S et al. Survival of Chilean patients with systemic lupus erythematosus. Seminars in Arthritis & Rheumatism 1994; 24: 1-11.
32. Mok C, Lee K, Ho C et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000; 39: 399-406.
33. Urowitz MB, Gladman D, Abu-Shakra M & Farewell V. Mortality studies in systemic lupus erythematosus: Results from a single center. III. Improved survival over 24 years. Journal of Rheumatology 1997; 24: 1061-1065.
34. Abu-Shakra M, Urowitz MB, Gladman DD & Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. Journal of Rheumatology 1995; 22: 1259-1264.
35. Uramoto KM, Michet CJJ, Thumboo J et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis & Rheumatism 1999; 42: 46-50.
36. Ward M, Pyun E & Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis & Rheumatism 1995; 38: 274-283.
37. Prete P, Majlessi A, Gilman S & Hamideh F. Systemic lupus erythematosus in men: A retrospective analysis in a Veterans Administration healthcare system population. Journal of Clinical Rheumatology 2001; 7: 142-150.
38. Studenski S, Allen N, Caldwell D et al. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis & Rheumatism 1987; 30: 1326-1332.
39. Reveille JD, Bertolucci A & Alarcon G. Prognosis in systemic lupus erythematosus: Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis & Rheumatism 1990; 33: 37-48.
40. Ginzler EM, Diamond HS, Weiner M et al. A multicenter study of outcome in SLE Part I: Entry variables as predictors of prognosis. Arthritis & Rheumatism 1982; 25: 601-611.
41. Walsh S, Algert C, Gergorio D et al. Divergent racial trends in mortality from systemic lupus erythematosus. Journal of Rheumatology 1995; 22: 1663-1668.
42. Urowitz MB, Bookman AA, Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus. American Journal of Medicine 1976; 60: 221-225.
43. Esdaile JM, Abrahamowicz M, MacKenzie T et al. The time-dependence of long-term prediction in lupus nephritis. Arthritis & Rheumatism 1994; 37: 359-368.
44. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in the 1980's: A survey of 570 patients. Seminars in Arthritis and Rheumatism 1991; 21: 55-64.
45. Wallace DJ, Podell T, Klineberg JR et al. Systemic lupus erythematosus survival patterns: Experience with 609 patients. JAMA 1981; 245: 934-938.
46. Nossent J. Course and prognosis of systemic lupus erythematosus disease activity index in black Carribean patients. Seminars in Arthritis and Rheumatism 1993; 23: 16-21.
47. McLaughlin J, Bombardier C, Farewell V et al. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis & Rheumatism 1994; 37: 559-567.
48. Donadio JJ, Hart G, Bergstralh E & Holley K. Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 1995; 4: 109-115.
49. El Shahawy M, Aswad S, Mendez R et al. Renal transplantation in systemic lupus erythematosus: A single-center experience with sixty-four cases. American Journal of Nephrology 1995; 15: 123-128.
50. Sibley JT, Olszynski W, Decoteau W & Sundaram M. The incidence and prognosis of central nervous systemic disease in systemic lupus erythematosus. Journal of Rheumatology 1992; 19: 47-52.
51. Malaviya A, Khan K, Tiwari S & Bhuyan U. Systemic connective tissue diseases in India VII. Deaths in systemic lupus erythematosus. Journal of the Association of Physicians of India 1984; 32: 313-316.
52. Kumar A, Malaviya A, Singh R et al. Survival in patients with systemic lupus erythematosus in India. Rheumatology International 1992; 12: 107-109.
53. Chandrasekaran A. Clinical and immunological profile of SLE in India. In Feng P (ed.) XIXth ILAR Congress of Rheumatology, pp 156-164. Communications Consultants, 1997.
54. Malaviya A, Chandrasekaran A, Kumar A & Sharmar P. Occasional series-lupus around the world systemic lupus erythematosus in India. Lupus 1997; 6: 690-700.
55. Iriya S, Capelozzi V, Calich I et al. Causes of death in patients with SLE in Sao Paulo Brazil: A study of 113 autopsies. Archives of Internal Medicine 2001; 161: 1557.
56. Gladman DD, Ginzler E, Goldsmith C et al. The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis & Rheumatism 1996; 39: 363-369.
57. Gladman D, Urowitz M, Goldsmith C et al. The reliability of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis & Rheumatism 1997; 40: 809-813.
58. Zonana-Nacach A, Barr SG, Magder LS & Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis & Rheumatism 2000; 43: 1801-1808.
59. Stoll T, Seifert B & Isenberg D. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. British Journal of Rheumatology 1996; 35: 248-254.
60. Zvaifler NJ. Chronic postrheumatic fever (Jacoud's arthritis). New England Journal of Medicine 1962; 267: 10.
61. Bywaters G. Jaccoud's syndrome; A sequel to the joint involvement of SLE. Clinical Rheumatic Diseases 1975; 1: 125-148.
62. Rothfield N. Clinical features of SLE. In Kelly W, Harris E, Ruddy S & Sledge C (eds) Textbook of Rheumatology, 10th edn, p 1070. Philadelphia, WB: Saunders, 1985.
63. Furie R & Chartash EK. Tendon rupture in SLE. Seminars in Arthritis and Rheumatism 1988; 18: 127-133.
64. Potasman I & Bassan H. Multiple tendon rupture in SLE: Case report and review of the literature. Annals of the Rheumatic Diseases 1984; 43: 347-348.
65. Pritchard C & Barney S. Patellar tendon rupture in SLE. Journal of Rheumatology 1989; 16: 786-788.
66. Halpern A, Horwitz B & Nagel D. Tendon ruptures associated with corticosteroid therapy. Western Journal of Medicine 1977; 127: 378-382.
67. Dubois E & Tuffanelli D. Clinical manifestations of SLE. Computer analysis of 520 cases. JAMA 1964; 190: 104-111.
68. Isenberg D & Snaith M. Muscle disease in SLE: A study of its nature, frequency, and cause. Journal of Rheumatology 1981; 8: 917-924.
69. Petri M. Systemic lupus erythematosus. Hopkins Lupus Cohort 1999 Update. Rheumatic Diseases Clinics of North America 2000; 26: 199-213.
70. Mont M & Jones L. Management of osteonecrosis in SLE. Rheumatic Diseases Clinics of North America 2000; 26: 279-309.
71. Gladman DD, Urowitz MB, Chaudhary-Ahluwalia V et al. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. Journal of Rheumatology 2001; 28: 761-765.
72. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update. Arthritis Care Research 1995; 8: 137-145.
73. Urowitz MB & Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 238-244.
74. Zizic T, Hungerford D & Stevens M. Ischemic bone necrosis in SLE. I. The early diagnosis of ischemic necrosis of bone. Medicine 1980; 59: 134-142.
75. Mont M & Hungerford D. Current concepts review: Non-traumatic avascular necrosis of the femoral head. Journal of Bone and Joint Surgery (Am) 1995; 77: 459-474.
76. Zangger P, Gladman DD, Urowitz MB & Bogoch ER. Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus. Journal of Rheumatology 2000; 27: 919-923.
77. Bluemke D, Petri M & Zerhan E. Femoral head perfusion and composition: MR imaging and spectroscopic evaluation of patients with SLE and risk for avascular necrosis. Radiology 1995; 197: 433-438.
78. Halland A, Klemp P, Bates D et al. Avascular necrosis of the hip in SLE: The role of magnetic resonance imaging. British Journal of Rheumatology 1993; 32: 972-976.
79. Kalla AA, Kotze TJ & Meyers OL. Metacarpal bone mass in systemic lupus erythematosus. Clinical Rheumatology 1992; 11: 1-8.
80. Formiga F, Moga I, Nolla JM et al. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1995; 54: 274-276.
81. Sinigaglia L, Varenna M, Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. Journal of Rheumatology 1999; 26: 1280-1284.
82. Gilboe I-M, Kvien TK, Haugeberg G & Husby G. Bone mineral density in systemic lupus erythematosus: Comparison with rheumatoid arthritis and healthy controls. Annals of the Rheumatic Diseases 2000; 59: 110-115.
83. Kalla AA, Fataar AB, Jessop SJ & Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis & Rheumatism 1993; 36: 1726-1734.
84. Ramsey-Goldman R, Dunn JE, Huang C-F et al. Risk of fracture of women with systemic lupus erythematosus. Arthritis & Rheumatism 1999; 42: 882-890.
85. Goodman WG, Coburn JW, Ramirez JA et al. Renal osteodystrophy in adults and children. In Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd edn, pp 304-434. New York: Raven Press
86. Ramsey-Goldman R, Dunlop D, Huang C et al. African-American (A-A) and Caucasian (C) women with lupus are at risk for low bone mineral density (BMD) (abstract). Journal of Bone and Mineral Research 2000; 15: S539.
87. Dhillon VB, Davies MC, Hall ML et al. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: A preliminary study with dual energy x-ray absorptiometry. Annals of the Rheumatic Diseases 1990; 49: 624-626.
88. Houssiau FA, Lefebvre C, Depresseux G et al. Trabecular and cortical bone loss in systemic lupus erythematosus. British Journal of Rheumatology 1996; 35: 244-247.
89. Sels F, Dequeker J, Verwilghen J & Mbuyi-Muamba J-M. SLE and osteoporosis: Dependence and/or independence on glucocorticoids. Lupus 1996; 5: 89-92.
90. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & Rheumatism 2001; 44: 1496-1503.
91. Neer R, Arnaud C, Zanchetta J et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 2001; 344: 1434-1441.
92. Lane N, Sanchez S, Modin G et al. Parathyroid hormone treatment can reverse steroid osteoporosis: Results of a randomized clinical trial. Journal of Clinical Investigation 1998; 102: 1627-1633.
93. Pettersson T, Pukkala E, Teppo L & Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1992; 51: 437-439.
94. Mellemkjaer L, Andersen V, Linet MS et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis & Rheumatism 1997; 40: 761-768.
95. Asherson RA, Block S, Houssian FA & Hughes GRV. Systemic lupus erythematosus and lymphoma: Association with an antiphospholipid syndrome. Journal of Rheumatology 1991; 18: 277-279.
96. Green JA, Dawson AA & Walker W. Systemic lupus erythematosus and lymphoma. Lancet 1978; ii: 753-756.
97. Agudelo CA, Schumacher HR, Glick JH & Molina J. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Report of 4 cases with ultrastructural studies in 2. Journal of Rheumatology 1981; 8: 69-78.
98. Cammarata RJ, Rodnan GP & Jensen WN. Systemic rheumatic diseases and malignant lymphoma. Archives of Internal Medicine 1963; 111: 330-337.
99. Abu-Shakra M, Gladman DD & Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis & Rheumatism 1996; 39: 1050-1054.
100. Posner MA, Gloster ES, Bonagura VR et al. Burkitt's lymphoma in a patient with systemic lupus erythematosus. Journal of Rheumatology 1990; 17: 380-382.
101. Lishner M, Hawker G & Amato D. Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematologica 1990; 84: 38-39.
102. Sultan SM, Ioannou Y & Isenberg DA. Is there an association of malignancy with SLE? An analysis of 276 patients under longterm review. Rheumatology 2000; 39: 1147-1152.
103. Cibere J, Sibley J & Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001; 10: 394-400.
104. Canoso JJ & Cohen AS. Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis & Rheumatism 1974; 17: 383-390.
105. Lewis RB, Castor CW, Knisley RE & Bole GG. Frequency of neoplasia in systemic lupus and rheumatoid arthritis. Arthritis & Rheumatism 1976; 19: 1256-1260.
106. Nyberg G, Eriksson O & Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis & Rheumatism 1981; 24: 648-650.
107. Blumenfeld Z, Lorber M, Yoffe N & Scharf Y. SLE: Predisposition for uterine cervical dysplasia. Lupus 1994; 3: 59-61.
108. Bateman H, Yazici Y, Peterson M & Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: A preliminary study. Lupus 2000; 9: 542-544.
109. Ramsey-Goldman R, Mattai SA, Schilling E et al. Increased risk of malignancy in patients with systemic lupus erythematosus. Journal of Investigative Medicine 1998; 46: 217-222.
110. Ramsey-Goldman R & Clarke A. Double trouble. Lupus 2001; 10: 388-391.
111. Nived O, Bengtsson A, Jonsen A et al. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 2001; 10: 500-504.
112. Nashi E, Clarke A, Joseph L & Fortin P. The incidence of cancer in patients with systemic lupus erythematosus. Arthritis & Rheumatism 2000; 43: S165 (abstract).
113. Sweeney DM, Manzi S, Janosky J et al. Risk of malignancy in female patients with systemic lupus erythematosus. Journal of Rheumatology 1995; 22: 1478-1482.
114. Ortiz AM, Gonzalez-Parra E, Alvarez-Costa G & Egido J. Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 1992; 60: 378-379.
115. Cras P, Franckx C & Martin J. Primary intracerebral lymphoma in systemic lupus erythematosus treated with immunosuppressives. Clinical Neuropathology 1989; 8: 200-205.
116. Leibowitz S & Schwartz RS. Malignancy as a complication of immunosuppressive therapy. Advances in Internal Medicine 1971; 17: 95-123.
117. Paolozzi FR & Goldberg J. Acute granulocytic leukemia following systemic lupus erythematosus. American Journal of Medicine 1985; 290: 32-35.
118. Hehir ME, Sewell JR & Hughes GRV. Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus. Annals of the Rheumatic Diseases 1979; 38: 94-95.
119. Butler RC, Thomas SM, Thompson JM & Keat ACS. Anaplastic myeloma in systemic lupus erythematosus. Annals of the Rheumatic Diseases 1984; 43: 653-655.
120. Elliott RW, Essenhigh DM & Morley AR. Cyclophosphamide treatment of systemic lupus erythematosus: Risk of bladder cancer exceeds benefits. British Medical Journal 1982; 284: 1160-1161.
121. Thrasher JB, Miller GJ & Wettlaufer JN. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. Journal of Urology 1990; 143: 119-121.
122. Talar-Williams C, Hijazi Y, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's Granulomatosis. Annals of Internal Medicine 1996; 124: 477-484.
123. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. American Journal of Epidemiology 1997; 145: 408-415.
124. Badui E, Garcia-Rubi D, Robles E et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985; 36: 431-441.
125. Feinglass E, Arnett F, Dorsch C et al. Neuropsychiatric manifestations of SLE: Diagnosis, clinical spectrum, and relationships to other features of the disease. Medicine 1976; 44: 323-339 (Baltimore).
126. Futrell E & Millikan C. Frequency, etiology and prevention of stroke in patients with SLE. Stroke 1989; 20: 583-591.
127. Jonsson H, Nived O & Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine 1989; 68: 141-150.
128. Kitagawa Y, Grotoh F, Koto A & Okayas H. Stroke in SLE. Stroke 1990; 21: 1533-1539.
129. Petri M, Roubenoff R, Dallal GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
130. Ward M. Premature morbidity from cardiovascular and cerebrovascular disease in women with SLE. Arthritis & Rheumatism 1999; 42: 338-346.
131. Mok C, Lau C & Wong R. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with SLE. Journal of Rheumatology 2001; 28: 766-771.
132. Lee C, Folsom A, Nieto F et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women. American Journal of Epidemiology 2001; 154: 758-764.
133. Gillum R. Risk factors for stroke in Blacks: A critical review. American Journal of Epidemiology 1999; 150: 1266-1274.
134. Gladman DD & Urowitz MB. Morbidity in systemic lupus erythematosus. Journal of Rheumatology 1987; 14 (supplement 13): 223-226.
135. Petri M, Perez-Gutthann S, Spence D & Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. American Journal of Medicine 1992; 93: 513-519.
136. Manzi S, Selzes F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis & Rheumatism 1999; 42: 51-60.
137. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatism 2001; 44: 2331-237.
138. Bulkley BH & Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. American Journal of Medicine 1975; 58: 243-264.
139. Hochberg MC, Petri M. The association of corticosteroid (CS) therapy with coronary heart disease (CHD) in patients with systemic lupus erythematosus (SLE): A meta-analysis. Arthritis & Rheumatism 1991; 34: R24.
140. Ettinger WH, Goldberg AP, Applebaum-Bowden D & Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effects of corticosteroids. American Journal of Medicine 1987; 83: 503-508.
141. Lockshin MD, Salmon JE & Roman MJ. Atherosclerosis and lupus: A work in progress. Arthritis & Rheumatism 2001; 44: 2215-2217.
142. Dooley MA, Hogan S, Jennette C & Falk R. Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney International 1997; 51: 1188-1195.
143. Austin H, Boumpas D, Vaughan E & Balow J. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrology, Dialysis and Transplantation 1995; 10: 1620-1628.
144. Mok C, Wong R & Lou C. Lupus nephritis in southern Chinese patients: Clinicopathologic findings and long-term outcome. American Journal of Kidney Disease 1999; 34: 315-324.
145. Ward M. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. American Journal of Kidney Disease 2000; 36: 516-524.
146. Hermosillo D, Holliday S, Sakland A et al. Autoantibody contributions to cognitive function in SLE. Lupus 2001; 10: s51 (abstract).
147. Hanly J, Hong C, Smith S & Fisk J. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis & Rheumatism 1999; 42: 728-734.
148. Arnett F, Reveille J, Moutsopoulos HM et al. Ribosomal-P antibodies in systemic lupus erythematosus. Arthritis & Rheumatism 1996; 39: 1833-1839.
149. Tziofas A, Tzortzakis N, Panou-Pomonis E et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: A large cohort of consecutive patients and patients with active central nervous system disease. Annals of the Rheumatic Disease 2001; 59: 99-104.
150. Cucurull E, Gharavi AE, Diri E et al. IgA anticardiolipin and anti-beta2 glycoprotein I are the most prevalent isotypes in African-American patients with systemic lupus erythematosus. American Journal of Medical Science 1999; 318: 55-60.
151. Menon S, Jameson-Shortall E, Newan S et al. A longitudinal analysis of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis & Rheumatism 1999; 42: 735-741.